Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Allied health and primary care (7)
  • Anaphylaxis (1)
  • x Biologicals (1)
  • Dermatology (1)
  • ENT (1)
  • Epidemiology (1)
  • Food allergy (2)
  • One Health (1)
  • Pediatrics (1)
  • Prevention (1)
  • Systems medicine (1)
Poster available until
Poster categories
  • Thematic Poster Session (1)
keywords
Session Reference
  • L-TPS02 (9)
  • L-TPS07 (11)
  • x L-TPS08 (1)
  • L-TPS09 (3)
  • L-TPS10 (1)
  • L-TPS12 (1)
  • L-TPS14 (1)
  • L-TPS19 (1)
  • L-TPS21 (5)
  • TPS06 (8)
  • TPS09 (2)
  • TPS11 (1)
  • TPS17 (4)
  • TPS18 (9)
  • TPS28 (1)
  • TPS29 (1)
  • TPS48 (1)
  • TPS51 (1)
  • TPS52 (6)
  • TPS54 (1)
  • TPS55 (10)
  • TPS56 (5)
  • TPS57 (1)
  • TPS63 (2)
  • TPS67 (9)
  • TPS69 (2)
1 results
Thumbnail

D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM